Dr. Musa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1101 Madison St
Ste 1500
Seattle, WA 98104Phone+1 206-991-2000Fax+1 206-320-3001- Is this information wrong?
Summary
- Dr. Fernanda Musa is an Gynecologic oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including the Swedish Cancer Institute and Providence Regional Medical Center Everett. She received her medical degree from Columbia University College of Physicians & Surgeons and has been in practice 10 years. She also speaks multiple languages, including Portuguese. She completed her fellowship in gynecologic oncology at New York University in New York and is experienced in complex gynecology, gynecologic oncology, clinical research, minimally invasive gynecologic surgery, and robotic surgery. She is interested in research and personalized cancer care and leads clinical trials at SCI.
Education & Training
- NYU Grossman School of MedicineFellowship, Gynecologic Oncology, 2011 - 2015
- NYU School of MedicineMS, Clinical Investigation, 2011 - 2013
- New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 2007 - 2011
- Columbia University Vagelos College of Physicians and SurgeonsClass of 2007
- Duke UniversityBS, Biology, 1998 - 2002
- Escola Americana do Rio de Janeiro (EARJ)IB, 1991 - 1998
Certifications & Licensure
- WA State Medical License 2017 - 2026
- NY State Medical License 2011 - 2018
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Start of enrollment: 2022 Aug 29
- Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer Start of enrollment: 2023 Dec 28
- ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) Start of enrollment: 2023 Jun 26
- Join now to see all
Publications & Presentations
PubMed
- 84 citationsPembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Fernanda B Musa, Robert Mannel, Mark S Shahin, Guilherme H Cantuaria, Eugenia Girda, C...> ;The New England Journal of Medicine. 2023 Jun 8
- 4 citationsDoubling down on the future of gynecologic oncology: The SGO future of the profession summit report.Stephanie V Blank, Warner K Huh, Maria Bell, Sarah Dilley, Melissa Hardesty, Ebony R Hoskins, Jason Lachance, Fernanda Musa, Emily Prendergast, B J Rimel, Mark Shahin,...> ;Gynecologic Oncology. 2023 Apr 1
- 2 citationsUterine Sarcomas: How to Navigate an Ever-Growing List of Subtypes.Molly Roy, Fernanda Musa, Sarah E Taylor, Marilyn Huang> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2022 Apr 1
- Join now to see all
Press Mentions
- Cancer Drug Shortages Lead to Heart-Wrenching Decisions at Washington HospitalsJune 5th, 2023
Committees
- Board of Directors, SGO 2022 - 2024
- Member, SGO Education Committee 2014 - 2016
Professional Memberships
- Member
- Fellow
- Society of Gynecologic OncologyMember
Other Languages
- Portuguese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: